219696-68-1

Basic information

• Product Name: bis(3,5-dimethoxyphenyl)-disulfide
• Synonyms: bis(3,5-dimethoxyphenyl)-disulfide
• CAS NO: 219696-68-1
• Molecular Weight: 338.449
• Mol File: 219696-68-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: bis(3,5-dimethoxyphenyl)-disulfide(CAS DataBase Reference)
• NIST Chemistry Reference: bis(3,5-dimethoxyphenyl)-disulfide(219696-68-1)
• EPA Substance Registry System: bis(3,5-dimethoxyphenyl)-disulfide(219696-68-1)

Safety Data

• Hazardous Substances Data: 219696-68-1(Hazardous Substances Data)

Upstream product

• 12775-96-1 copper 
• 10272-07-8 3.5-dimethoxyaniline 
• 140-89-6 potassium ethyl xanthogenate 
• 86988-56-9 3,5-Dimethoxy-benzenediazonium; chloride 

Downstream Products

• 19689-66-8 3,5-dimethoxybenzenethiol 
• 219696-67-0 2-(3,5-dimethoxyphenylthio)benzoic acid 
• 1026883-23-7 5-chloro-3-[(3,5-dimethoxyphenyl)thio]-1H-indole-2-carboxylic acid 

Relevant articles and documents

New arylthioindoles: Potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies

Arylthioindoles (ATIs) that possess a 3-methoxyphenylthio or a 3,5-dimethoxyphenylthio moiety at position 2 of the indole ring were effective tubulin assembly inhibitors, but weak inhibitors of MCF-7 cell growth. ATIs bearing a 3-(3,4,5-trimethoxyphenyl)thio moiety were potent tubulin polymerization inhibitors, with IC50s in the 2.0 (35) to 4.5 (37) μM range. They also inhibited MCF-7 cell growth at nanomolar concentrations. The 3,4,5-trimethoxy substituted ATIs showed potencies comparable to those of the reference compounds colchicine and combretastatin A-4 in both tubulin assembly and cell growth inhibition assays. Dynamics simulation studies correlate well with the observed experimental data. Furthermore, from careful analysis of the biological and in silico data, we can now hypothesize a basic pharmacophore for this class of compounds.

TRICYCLIC FUSED HETEROCYCLE COMPOUNDS, PROCESS FOR PREPARING THE SAME AND USE THEREOF

Compounds represented by formula (1),???whereinX is, for example, CH, CH2, CHR (wherein R is a lower alkyl group or a substituted lower alkyl group) or CRR' (wherein R and R' are the same as the above defined R);Y is, for example, CH, CH2or C=O;Z is, for exampe, O, S, S=O or SO2;U is C or N;R1to R4are each independently, for example, a hydrogen atom, OR, SR (wherein R is the same as defined above), or an aromatic ring, a substituted aromatic ring or a heterocycle;???at least one of R5and R8is, for example, OH and the remaining of R5and R8are each independently, for example, a hydrogen atom or OH, optical isomers thereof, conjugates thereof or pharmaceutically acceptable salts thereof are provided. These compounds are characterized in having a wide range of pharmacological actions such as an excellentrelaxing action of tracheal smooth muscles, an inhibition of airway hypersensitivity and an inhibition of infiltration of inflammatory cells into the airway and, in addition, high safety.